<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clone size has been postulated as a prognostic factor in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), though it has not been studied systematically </plain></SENT>
<SENT sid="1" pm="."><plain>We tested its impact (&lt;100% vs. 100%) in a population of 216 MDS with chromosome 7 abnormalities (-7/7q-) (n=84), <z:mp ids='MP_0004027'>trisomy</z:mp> 8 (n=99), 20q deletion (n=28) and loss of Y chromosome (n=26) </plain></SENT>
<SENT sid="2" pm="."><plain>Focusing on the survival the bad prognosis of -7/7q- was independent of the clone size (9.3 vs. 5.0 months, P=0.188, not significant) but <z:mp ids='MP_0004027'>trisomy</z:mp> 8 cases with 100% aberrant metaphases did reveal a worse prognosis (13.9 vs. 5.9 months, P=0.003) </plain></SENT>
</text></document>